Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"
Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"

NCT05919342

RecruitingNA

Sponsor: NHS Greater Glasgow and Clyde

Conditions: Heart Failure, Cardiovascular Diseases

Interventions: NT-proBNP

Countries: United States, Canada, Denmark, Sweden, United Kingdom

This is an international prospective, multicentre, unblinded, randomised-controlled trial. The primary aim is to assess a targeted screening strategy to detect undiagnosed heart failure in high-risk patients.

Eligibility overview

Sex: ALL

Age: 40 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Male or female ≥40 years of age
* Informed consent
* Two or more of the following risk factors for heart failure:

  1. Coronary artery disease (either a previous documented type 1 myocardial infarction or coronary artery bypass grafting or percutaneous coronary intervention or documented stenosis of an epicardial coronary artery \[50% left main stem or \>70% left anterior descending, circumflex or right coronary artery\])
  2. An established diagnosis of diabetes (type 1 or type 2)
  3. Persistent or permanent atrial fibrillation (not paroxysmal atrial fibrillation)
  4. Previous ischemic or embolic stroke
  5. Peripheral arterial disease (previous surgical or percutaneous revascularisation or a documented stenosis greater than 50% of a major peripheral arterial vessel).
  6. Chronic kidney disease (defined as an estimated glomerular filtration rate \<60mL/min/1.73m2 or eGFR 60-90mL/min/1.73m2 and UACR \>300mg/g).
  7. Regular loop diuretic use (any dose at any dosing interval) for \>30 days.
  8. COPD (evidenced by one of the following: PFTs showing airway obstruction, diagnosis by respiratory physician, CT scan reporting presence of emphysema or treatment with national guideline advocated COPD therapy).

Exclusion Criteria:

* Inability to give informed consent e.g., due to significant cognitive impairment
* Previous documented diagnosis of heart failure
* Current renal replacement therapy
* Anyone who, in the investigators' opinion, is not suitable to participate in the trial for other reasons e.g., a diagnosis which may compromise survival over the study period
Locations (7)
  • Cleveland, Ohio, United States
  • Vancouver, British Columbia, Canada
  • Montreal, Quebec, Canada
  • Copenhagen, Denmark
  • Stockholm, Sweden
  • Uppsala, Sweden
  • Glasgow, Scotland, United Kingdom